Finland conducts a significant amount of high-quality brain research. The aim of the National Neurocenter is to promote innovation in neuroscience, strengthen national and international research collaboration, increase the visibility of research, and facilitate patient recruitment for studies.
On this page, you will find contact information for clinical studies that are currently recruiting participants. Please get in touch if you would like your own study to be added to the list.
Studies recruiting patients
NCT06309966
Phase 2/3 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of BHV-7000 in subjects with treatment-resistant focal onset epilepsy.
Study organization / site and principal investigator:
Helsinki HUS: Reina Roivainen
Kuopio KYS: Reetta Kälviäinen
Tampere TAYS: Jukka Peltola
Contact information for the different study sites:
The study investigates the disease progression of hereditary frontotemporal lobar degeneration and aims to develop new biomarkers for diagnosis and monitoring.
You may be eligible to participate if:
You are over 18 years old
You have a confirmed hereditary frontotemporal lobar degeneration caused by a genetic mutation
You are a first-degree relative of someone diagnosed with hereditary frontotemporal lobar degeneration
You are not pregnant
Participation in the study:
Participation in the study lasts one to two days, and additional information will be collected during annual follow-up visits. The study will run for a total of 10 years. All study visits are free of charge.
Person responsible for the study:MD, Associate Professor Johanna Krüger, Oulu University Hospital and University of Oulu
If you would like to participate in the study or need more information, please contact the study site:
Study site Oulu:
Principal Investigator: MD, Associate Professor Johanna Krüger
Contact: Study Nurse Pirkko Holappa, [email protected], 040 506 2344
Study site Kuopio: Kuopio University Hospital and University of Eastern Finland, Brain Research Unit
Principal Investigator: Associate Professor Eino Solje
Contact: Study Nurse Jenni Niinimäki, [email protected], 050 344 3867
Phase 3 multicenter study investigating the efficacy and safety of rimegepant compared to placebo as a preventive treatment for chronic migraine in adolescents aged 12–17 years.
Adolescents may be eligible to participate if they meet the following criteria:
Age 12–17 years
Chronic migraine for at least 6 months
Migraine attacks occur on at least 8 days per month
Untreated migraine attacks typically last between 4 and 72 hours
If you or your child/ward would like to participate in the study or would like more information, please contact the study site closest to you:
Kuopio University Hospital, Pediatric Neurology Unit
Principal Investigator: Jarkko Kirjavainen
Contact: Study nurse Eija Lappalainen, [email protected], 044 717 4907
Tampere University Hospital, Pediatric Clinical Research Center Peetu
This clinical trial evaluates whether a new investigational combination drug can improve memory, thinking, and daily functioning in people with Alzheimer’s disease. The study also assesses the safety and tolerability of the study medication.
You may be eligible to participate if:
You are 60–85 years old
You have a physician-confirmed diagnosis of Alzheimer’s disease in a mild or moderate stage
You have an adult support person who can accompany you to all study visits
The study medication and all related examinations are free of charge for participants. Travel expenses for study visits will be reimbursed.
The study is conducted in Kuopio at the Brain Research Unit.
Participation involves approximately 12–14 visits. If you join the open-label extension phase, the total number of visits will be about 18–20.
If you or your relative are interested in participating, please contact: Brain Research Unit, +35850 565 0598 or [email protected]
Researcher, if you would like your study to appear on this page, please contact Juulia Taavitsainen ([email protected]).
The National Neurocenter collaborates with the Finnish Brain Association (Suomen Aivot ry) to launch Finland’s Brain Health Strategy, which aims to promote good brain health throughout the lifespan. Brain health affects everything—memory, learning, mood, work ability, and quality of life. By taking care of our brains, we take care of ourselves and our society.
The Brain Health Strategy concerns all citizens. Healthy brains support daily functioning, learning, and mood. By preventing brain diseases and promoting brain health, everyone has better opportunities to live a full life. The strategy guides society in creating conditions that make brain-healthy choices easier and ensure that information about brain health is accessible to all.
What can you do to maintain your brain health?
Exercise regularly. Physical activity improves circulation and helps keep your brain alert.
Eat a balanced diet. The brain needs nutrients to function optimally.
Get enough sleep. Adequate sleep supports learning, concentration, and recovery.
Maintain social connections. Interacting with others strengthens brain function and prevents loneliness.
Challenge your brain by learning new things. Every new experience reinforces neural networks.
